DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

Phase 2

Recruiting

Conditions: Advanced Nasopharyngeal Carcinoma

Interventions: Radiation: SBRT

First Posted Date: 2022-12-15

Last Posted Date: 2022-12-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT05652192

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

DLCS for Predicting Neoadjuvant Chemotherapy Response

Recruiting

Conditions: Gastric Cancer
CT Images
Deep Learning
Neoadjuvant Chemotherapy
Tumor Regression Grade

First Posted Date: 2022-11-15

Last Posted Date: 2022-11-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 1100

Registration Number: NCT05617469

Locations: 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

Whether Opioids Are Factor That Induced POD?

Not Applicable

Completed

Conditions: Postoperative Delirium

Interventions: Drug: Sufentanil Citrate
Drug: Ropivacaine 0.75% Injectable Solution
Procedure: Epidural catheter

First Posted Date: 2022-10-27

Last Posted Date: 2022-10-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 130

Registration Number: NCT05596071

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: H101, Camrelizumab

First Posted Date: 2022-10-04

Last Posted Date: 2022-10-04

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 25

Registration Number: NCT05564897

Locations: 🇨🇳
Hua Wang, Hangzhou, Zhejiang, China

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

Phase 2

Recruiting

Conditions: Gastrointestinal Cancer

Interventions: Drug: Pemigatinib Pill

First Posted Date: 2022-09-29

Last Posted Date: 2022-09-29

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05559775

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Tislelizumab combined with GEMOX (GOT) regimen

First Posted Date: 2022-09-28

Last Posted Date: 2025-02-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05557578

Locations: 🇨🇳
Jia Wu, Hanzhou, Zhejiang, China
🇨🇳
1# Banshan East Rd. Zhejiang cancer hospital, Hangzhou, Zhejiang, China

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC

Recruiting

Conditions: Metastatic Breast Cancer in the Liver

Interventions: Drug: Chemotherapy

First Posted Date: 2022-09-22

Last Posted Date: 2022-09-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05550090

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

Phase 2

Recruiting

Conditions: SCLC,Extensive Stage

Interventions: Radiation: Thoracic radiotherapy

First Posted Date: 2022-09-16

Last Posted Date: 2022-09-16

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 42

Registration Number: NCT05544149

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Gastric Cancer

Interventions: Drug: Nab-PTX,S-1,Tirelizumab
Radiation: Chemoradiation

First Posted Date: 2022-09-06

Last Posted Date: 2022-09-06

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 33

Registration Number: NCT05528367

Locations: 🇨🇳
Liu luying, Hangzhou, Zhejiang, China

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Endostatin and Capecitabine

First Posted Date: 2022-08-24

Last Posted Date: 2022-08-24

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 41

Registration Number: NCT05514275

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
People's Hospital of Quzhou, Quzhou, Zhejiang, China
🇨🇳
the First Hospital of Jiaxing, Jiaxing, Zhejiang, China

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy